PBPK Modeling and Simulation Services

Building Prospective Clinical Knowledge From Your In Vitro ADME Data 

Physiologically-based pharmacokinetic (PBPK) models describe and predict the handling of drugs by the body in a realistic way based on demography, physiology, biochemistry and genetics. We integrate this information with in vitro drug absorption, metabolism and transport data to simulate and predict pharmacokinetics in virtual patient populations. Such ‘population-based’ PBPK modeling is increasingly being used in regulatory review to facilitate decisions on the necessity for specific clinical studies, to inform study design and guide appropriate labeling language.

Certara is the leader in mechanistic pharmacokinetics with an international reputation for in vitro-in vivo extrapolation of drug absorption, distribution, metabolism and elimination (ADME) data. In addition to licensing the Simcyp Population-based Simulator, we offer consultancy services on all aspects of drug ADME and PK/PD data analysis and interpretation.

Certara can review and critique available pre-clinical ADME and physical chemistry data to ensure that they are fit-for-purpose. Together with the client, Certara personnel help design a PBPK modelling and simulation strategy to help answer a wide variety of clinical questions without having to resort to in vivo study. This service is ideally suited to those clients who do not have the resources or time to use our simulation technology directly. Certara offers a bespoke turn-key PBPK modeling and simulation (M&S) solution, including data review, project design, analysis, interpretation and report writing.

Benefits of PBPK Modeling and Simulation

Here are just a few examples of where our Consultancy has helped clients:

  • Predicting first-time-in-human dose
  • Predicting and avoiding unnecessary drug-drug interaction (DDI) studies
  • Predicting pediatric pharmacokinetics and pediatric formulation development
  • Evaluating the potential impact of genetic differences
  • Evaluating potential ethnic differences in Japanese and Chinese populations
  • Facilitating drug candidate lead optimization
  • Accelerating formulation development
  • Predicting the impact of hepatic/renal disease on drug kinetics

Our experts can help you to construct a cumulative knowledgebase, accessible across your team for enhanced collaboration and decision making.